Survival benefit of living-donor liver transplant
Survival benefit of living-donor liver transplant
LDCOP and LICOP invite the authors to discuss their study’s findings, which challenge current perceptions regarding when LDLT survival benefit occurs.
- 2:00 PM - 3:00 PM EDT
- Virtual, as part of the AST Journal Club Series.
"Survival benefit of living-donor liver transplant"
(JAMA Surg. 2022 Oct 1;157(10):926-932. doi: 10.1001/jamasurg.2022.3327.)
In this article:
Despite the acceptance of living-donor liver transplant (LDLT) as a lifesaving procedure for end-stage liver disease, it remains underused in the United States. Quantification of lifetime survival benefit and the Model for End-stage Liver Disease incorporating sodium levels (MELD-Na) score range at which benefit outweighs risk in LDLT is necessary to demonstrate its safety and effectiveness. [Based on a case-controlled study, the authors found a] LDLT is associated with a substantial survival benefit to patients with end-stage liver disease even at MELD-Na scores as low as 11. The findings of this study suggest that the life-years gained are comparable to or greater than those conferred by any other lifesaving procedure or by a deceased-donor liver transplant. This study’s findings challenge current perceptions regarding when LDLT survival benefit occurs.
Speaker:
- Whitney Jackson, MD • University of Colorado Medicine, Aurora, CO
- John Malamon, PhD, MS • University of Colorado Medicine, Aurora, CO
Moderator:
- AnnMarie Liapakis, MD • Yale New Haven Transplantation Center, New Haven, CT
- Anjana Pillai, MD, FAST • University of Chicago Medicine, Chicago, IL
Co-hosted by AST's Living Donor Community of Practice (LDCOP) and Liver and Intestinal Community of Practice (LICOP). All AST Journal Clubs, and featured AST/AJT Journal Clubs, are free but registration is required to attend live.
Learn more about the AST Journal Club Series
Advertisements
